[Translation] A randomized, randomized, randomized controlled trial comparing domvanalimab and cepalizumab plus chemotherapy versus nivolumab plus chemotherapy in subjects with previously untreated locally advanced unresectable or metastatic adenocarcinoma of the stomach, gastroesophageal junction, and esophagus. Open, multicenter phase III trial
本研究是一项在既往未经治疗的局部晚期无法切除或转移的胃、GEJ 和食管腺癌受试者中评价 Domvanalimab 和赛帕利单抗联合化疗对比纳武利尤单抗联合化疗的总生存期。包括比较 PD-L1 高表达受试者中 Domvanalimab + 赛帕利单抗 + 化疗对比纳武利尤单抗 + 化疗的总生存期 (OS) 及比较所有随机分配受试者中 Domvanalimab + 赛帕利单抗 + 化疗对比纳武利尤单抗 + 化疗的 OS。
[Translation] This study is a study to evaluate overall survival of domvanalimab plus cepalizumab plus chemotherapy versus nivolumab plus chemotherapy in subjects with previously untreated locally advanced unresectable or metastatic adenocarcinoma of the stomach, GEJ, and esophagus. Expect. Including comparing the overall survival (OS) of Domvanalimab + cepalizumab + chemotherapy versus nivolumab + chemotherapy in subjects with high PD-L1 expression and comparing Domvanalimab + cepalizumab in all randomly assigned subjects OS of anti+chemotherapy versus nivolumab+chemotherapy.